Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
P M Chavassieux, … , A J Yates, P J Meunier
P M Chavassieux, … , A J Yates, P J Meunier
Published September 15, 1997
Citation Information: J Clin Invest. 1997;100(6):1475-1480. https://doi.org/10.1172/JCI119668.
View: Text | PDF
Research Article Article has an altmetric score of 12

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

  • Text
  • PDF
Abstract

Research Article

Authors

P M Chavassieux, M E Arlot, C Reda, L Wei, A J Yates, P J Meunier

×

Total citations by year

Year: 2025 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 Total
Citations: 2 1 4 3 9 6 6 9 8 11 18 21 18 22 21 17 19 18 23 24 31 17 23 14 15 12 4 2 378
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (378)

Title and authors Publication Year
Development of a Medication-Related Osteonecrosis of the Jaw Prediction Model Using the FDA Adverse Event Reporting System Database and Machine Learning
Toriumi S, Shimokawa K, Yamamoto M, Uesawa Y
Pharmaceuticals 2025
Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption
Aguirre JI, Croft SM, Castillo EJ, Cruz-Camacho CJ, Kimmel DB
Bone Reports 2025
Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy
Qiu S, Dhaliwal R, Divine G, Warner E, Rao SD
Journal of Bone and Mineral Research 2024
Clinical Data for Parametrization of In Silico Bone Models Incorporating Cell-Cytokine Dynamics: A Systematic Review of Literature.
Ledoux C, Boaretti D, Sachan A, Müller R, Collins CJ
Frontiers in Bioengineering and Biotechnology 2022
Added effect of 1% topical alendronate in intra-bony and inter-radicular defects as part of step II periodontal therapy: a systematic review with meta-analysis and trial sequential analysis.
Arena C, Caponio VCA, Zhurakivska K, Lo Russo L, Lo Muzio L, Troiano G
BMC oral health 2022
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2022
Interest of Bone Histomorphometry in Bone Pathophysiology Investigation: Foundation, Present, and Future.
Chavassieux P, Chapurlat R
Frontiers in Endocrinology 2022
Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years
HH Malluche, J Chen, F Lima, LJ Liu, MC MonierFaugere, D Pienkowski
JBMR Plus 2021
Bisphosphonates impair the onset of bone formation at remodeling sites
PR Jensen, TL Andersen, P Chavassieux, JP Roux, JM Delaisse
Bone 2021
Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis
K Aoki, S Matsunaga, S Ito, T Shibahara, T Nomura, H Matsuzaki, S Abe, A Yamaguchi
Journal of Bone and Mineral Metabolism 2021
Bone Regulators and Osteoporosis Therapy
PH Stern
2020
Bone Regulators and Osteoporosis Therapy
PH Stern
2020
Bone Regulators and Osteoporosis Therapy
PH Stern
2020
Osteoporosis Treatments Affect Bone Matrix Maturation in a Rat Model of Induced Cortical Remodeling
RD Ross, K Anderson, R Davison, BM ElMasri, CM Andreasen, TL Andersen, DR Sumner
JBMR Plus 2020
Zoledronate
IR Reid, JR Green, KW Lyles, DM Reid, U Trechsel, DJ Hosking, DM Black, SR Cummings, RG Russell, EF Eriksen
Bone 2020
Circular RNA atlas in osteoclast differentiation with and without alendronate treatment
J Lin, S Ma, C Zhu, C Chen, W Lin, C Lin, G Huang, Z Ding
Journal of orthopaedic surgery and research 2020
The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study
F Gossiel, MA Paggiosi, KE Naylor, EV McCloskey, J Walsh, N Peel, R Eastell
Bone 2020
Subchondral bone deterioration in femoral heads in patients with osteoarthritis secondary to hip dysplasia: A case–control study
G Li, L Chen, Q Zheng, Y Ma, C Zhang, MH Zheng
Journal of Orthopaedic Translation 2020
Comparative Analysis of Bone Mechanical Properties of Adipose-Derived Mesenchymal Stem Cells and Raloxifene in Treatment of Osteoporosis
C Piao, Z Li, J Ding, D Kong
Journal of Hard Tissue Biology 2020
Update on Menopausal Hormone Therapy for Fracture Prevention
JJ Stepan, H Hruskova, M Kverka
Current Osteoporosis Reports 2019
Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial: CORTICAL ILIAC BONE HISTOMORPHOMETRY IN THE FREEDOM TRIAL
P Chavassieux, N Portero-Muzy, JP Roux, S Horlait, DW Dempster, A Wang, RB Wagman, R Chapurlat
Journal of Bone and Mineral Research 2019
Raman spectroscopy investigation shows that mineral maturity is greater in CD-1 than in C57BL/6 mice distal femurs after sexual maturity
C Fayolle, M Labrune, JP Berteau
Connective Tissue Research 2019
Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta
D Olvera, R Stolzenfeld, E Fisher, B Nolan, MS Caird, KM Kozloff
Journal of Bone and Mineral Research 2019
Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
P Chavassieux, R Chapurlat, N PorteroMuzy, JP Roux, P Garcia, JP Brown, C Libanati, RW Boyce, A Wang, A Grauer
Journal of Bone and Mineral Research 2019
Comparison of bone biomechanical properties after bone marrow mesenchymal stem cell or alendronate treatment in an osteoporotic animal model
C Piao, Z Li, J Ding, D Kong
Biomedizinische Technik/Biomedical Engineering 2019
Osteoclast-secreted SLIT3 coordinates bone resorption and formation
Beom-Jun Kim, Young-Sun Lee, Sun-Young Lee, Wook-Young Baek, Young Jin Choi, Sung Ah Moon, Seung Hun Lee, Jung-Eun Kim, Eun Ju Chang, Eun-Young Kim, Jin Yoon, Seung-Whan Kim, Sung Ho Ryu, Sun-Kyeong Lee, Joseph A. Lorenzo, Seong Hee Ahn, Hyeonmok Kim, Ki-Up Lee, Ghi Su Kim, Jung-Min Koh
Journal of Clinical Investigation 2018
Effect of Quercetin on Bone Mineral Status and Markers of Bone Turnover in Retinoic Acid-Induced Osteoporosis
N Oršolić, Ž Jeleč, J Nemrava, V Balta, G Gregorović, D Jeleč
Polish Journal of Food and Nutrition Sciences 2018
Updates in CKD-Associated Osteoporosis
P Khairallah, TL Nickolas
Current Osteoporosis Reports 2018
LRRK1 regulation of actin assembly in osteoclasts involves serine 5 phosphorylation of L-plastin: SI et al
M Si, H Goodluck, C Zeng, S Pan, EM Todd, SC Morley, X Qin, S Mohan, W Xing
Journal of Cellular Biochemistry 2018
Young’s modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years
D Pienkowski, CL Wood, HH Malluche
Osteoporosis International 2018
Osteoporosis and quality of bone
J Štěpán
Vnitrni lekarstvi 2018
Materials for Bone Disorders
SM Ott
Materials for Bone Disorders 2017
Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system
EL Caires, MC Bezerra, AF de Junqueira, SM de Fontenele, SC de Andrade, CB dAlva
Revista Brasileira de Reumatologia (English Edition) 2017
Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties
S Ma, EL Goh, A Jin, R Bhattacharya, OR Boughton, B Patel, A Karunaratne, NT Vo, R Atwood, JP Cobb, U Hansen, RL Abel
Scientific Reports 2017
Myeloproliferative Neoplasms
DL Longo, JL Spivak
New England Journal of Medicine 2017
Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats
A Takakura, JW Lee, K Hirano, Y Isogai, T Ishizuya, R Takao-Kawabata, T Iimura
Bone Research 2017
Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats
T Shimizu, T Tanaka, T Kobayashi, I Kudo, M Nakatsugawa, A Takakura, R Takao-Kawabata, T Ishizuya
Bone Reports 2017
High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome: HIGH TURNOVER IN MICE WITH HAJDU-CHENEY SYNDROME
N Vollersen, I Hermans-Borgmeyer, K Cornils, B Fehse, T Rolvien, I Triviai, A Jeschke, R Oheim, M Amling, T Schinke, TA Yorgan
Journal of Bone and Mineral Research 2017
Do acid suppressive drugs (pantoprazole and ranitidine) attenuate the protective effect of alendronate in estrogen-deficient osteoporotic rats?
AS Osman, DA Labib, AI Omar
The Egyptian Rheumatologist 2017
Femoral head trabecular micro-architecture in patients with osteoporotic hip fractures: Impact of bisphosphonate treatment
BH Yoon, JG Kim, YK Lee, YC Ha, KH Koo, JH Kim
Bone 2017
Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in low- and high energy fracture conditions
EA Zimmermann, E Schaible, B Gludovatz, FN Schmidt, C Riedel, M Krause, E Vettorazzi, C Acevedo, M Hahn, K Püschel, S Tang, M Amling, RO Ritchie, B Busse
Scientific Reports 2016
Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates
J Ward, C Wood, K Rouch, D Pienkowski, HH Malluche
Osteoporosis International 2016
Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells
TJ Heino, JJ Alm, HJ Halkosaari, VV Välimäki
Acta Orthopaedica 2016
Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis
DB Burr
Clinical Reviews in Bone and Mineral Metabolism 2016
Free Fatty Acid Receptor 4 (GPR120) Stimulates Bone Formation and Suppresses Bone Resorption in the Presence of Elevated n-3 Fatty Acid Levels
SH Ahn, SY Park, JE Baek, SY Lee, WY Baek, SY Lee, YS Lee, HJ Yoo, H Kim, SH Lee, DS Im, SK Lee, BJ Kim, JM Koh
Endocrinology 2016
Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use
SR Mastaglia, G Aguilar, B Oliveri
European Journal of Rheumatology 2016
Tratamento da osteoporose pós‐menopáusica: um algoritmo baseado na literatura para uso no sistema público de saúde
EL Caires, MC Bezerra, AF de Junqueira, SM de Fontenele, SC de Andrade, CB dAlva
Revista brasileira de reumatologia 2016
The Duration and Safety of Osteoporosis Treatment
S Silverman, B Abrahamsen
2016
Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation: OSTEOCLAST TGF-β RECEPTOR SIGNALING INDUCES WNT1 SECRETION
MM Weivoda, M Ruan, L Pederson, C Hachfeld, RA Davey, JD Zajac, JJ Westendorf, S Khosla, MJ Oursler
Journal of Bone and Mineral Research 2015
Bone quality and biomechanical function: A lesson from human ossicles
F Duboeuf, B Burt-Pichat, D Farlay, P Suy, E Truy, G Boivin
Bone 2015
Multi-level characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone
P Milovanovic, EA Zimmermann, C Riedel, A Scheidt, L Herzog, M Krause, D Djonic, M Djuric, K Püschel, M Amling, RO Ritchie, B Busse
Biomaterials 2015
Jaw Bone Samples From Bisphosphonate-Treated Patients: A Pilot Cohort Study: Jaw Bone Samples from BP-Treated Patients
C Cardemil, P Thomsen, CL Wexell
Clinical Implant Dentistry and Related Research 2015
Three-Times-Weekly Administration of Teriparatide Improves Vertebral and Peripheral Bone Density, Microarchitecture, and Mechanical Properties Without Accelerating Bone Resorption in Ovariectomized Rats
R Takao-Kawabata, Y Isogai, A Takakura, Y Shimazu, E Sugimoto, O Nakazono, I Ikegaki, H Kuriyama, S Tanaka, H Oda, T Ishizuya
Calcified Tissue International 2015
Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease
SM Ott
Seminars in Dialysis 2015
Early Effects of Single and Low-Frequency Repeated Administration of Teriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats
Y Isogai, R Takao-Kawabata, A Takakura, E Sugimoto, O Nakazono, I Ikegaki, H Kuriyama, T Ishizuya
Calcified Tissue International 2015
Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions
A Sugie-Oya, A Takakura, R Takao-Kawabata, H Sano, Y Shimazu, Y Isogai, A Yamaguchi, T Ishizuya
Journal of Bone and Mineral Metabolism 2015
Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model
YS Chung, HC Kang, T Lee
Yonsei Medical Journal 2015
Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials
Qinggang Zhang, Jing Qian, Yuchang Zhu
International journal of clinical and experimental medicine 2015
Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
C Wang, G Zhang, M Gu, J Fan, J Chen, G Zhang, B Li
Journal of Investigative Surgery 2015
From histology to micro-CT: Measuring and modeling resorption cavities and their relation to bone competence
J Vanderoost
World journal of radiology 2014
Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats
S Takeda, SY Smith, T Tamura, H Saito, F Takahashi, R Samadfam, S Haile, N Doyle, K Endo
Calcified Tissue International 2014
The Roles of Small GTPases in Osteoclast Biology
MJ Oursler
Orthopedic & Muscular System 2014
Molecular and cellular basis of bone resorption
R Gruber
Wiener Medizinische Wochenschrift 2014
Bisphosphonates and bone quality
M Pazianas, S der Geest, P Miller
BoneKEy Reports 2014
Review: Epidemiology and Pathophysiology of Atypical Femur Fractures
AC Ng, MA Png, DT Chua, JS Koh, TS Howe
Current Osteoporosis Reports 2014
Bone Histomorphometry of Transiliac Paired Bone Biopsies After 6 or 12 Months of Treatment With Oral Strontium Ranelate in 387 Osteoporotic Women: Randomized Comparison to Alendronate: EFFECTS OF SrRan VS. ALN ON BONE HISTOMORPHOMETRY
P Chavassieux, PJ Meunier, JP Roux, N Portero-Muzy, M Pierre, R Chapurlat
Journal of Bone and Mineral Research 2014
Giant osteoclasts in patients under bisphosphonates
F Mac-Way, A Trombetti, C Noel, MH Lafage-Proust
BMC clinical pathology 2014
Bisphosphonate-Related Osteonecrosis of the Jaws and Its Array of Manifestations
GD Rabelo, JN Assunção, P Chavassieux, HA Soares, FA Alves, CA Lemos
Journal of Maxillofacial and Oral Surgery 2014
Does mechanical stimulation really protect the architecture of trabecular bone? A simulation study
MM Maurer, R Weinkamer, R Müller, D Ruffoni
Biomechanics and Modeling in Mechanobiology 2014
Bone safety with risedronate: histomorphometric studies at different dose levels and exposure
RR Recker, LG Ste-Marie, P Chavassieux, MR McClung, MW Lundy
Osteoporosis International 2014
Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients
B Jobke, P Milovanovic, M Amling, B Busse
Bone 2014
Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
YL Ma, QQ Zeng, AY Chiang, D Burr, J Li, H Dobnig, A Fahrleitner-Pammer, D Michalská, F Marin, I Pavo, JJ Stepan
Bone 2014
A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy
K Iwata, T Mashiba, T Hitora, Y Yamagami, T Yamamoto
Bone 2014
Evaluating optimal combination of clodronate and bioactive glass for dental application
K Rosenqvist, S Airaksinen, M Vehkamäki, AM Juppo
International Journal of Pharmaceutics 2014
Bisphosphonates and Connexin 43: A Critical Review of Evidence
P Sadr-Eshkevari, S Ashnagar, A Rashad, M Dietz, J Jackowski, A Abdulazim, N Prochnow
Cell communication & adhesion 2014
Inhibition of Cathepsin K Increases Modeling-Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys: ODANACATIB STIMULATES CORTICAL BONE FORMATION IN OVARIECTOMIZED MONKEYS
BL Pennypacker, CM Chen, H Zheng, MS Shih, M Belfast, R Samadfam, LT Duong
Journal of Bone and Mineral Research 2014
Reference Module in Biomedical Sciences
DL Sackett, RB Haynes
2014
Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab: MATHEMATICAL MODELING OF OSTEOPOROSIS TREATMENT BY DENOSUMAB
S Scheiner, P Pivonka, DW Smith, CR Dunstan, C Hellmich
International Journal for Numerical Methods in Biomedical Engineering 2013
The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing
J Jeyabalan, B Viollet, P Smitham, SA Ellis, G Zaman, C Bardin, A Goodship, JP Roux, M Pierre, C Chenu
Osteoporosis International 2013
Bisphosphonate Treatment for Children With Disabling Conditions
AM Boyce, LL Tosi, SM Paul
PM&R 2013
An In Vitro Assessment of Fibroblast and Osteoblast Response to Alendronate-Modified Titanium and the Potential for Decreasing Fibrous Encapsulation
X Hu, KG Neoh, Z Shi, ET Kang, W Wang
Tissue Engineering Part A 2013
Micro-morphological properties of osteons reveal changes in cortical bone stability during aging, osteoporosis, and bisphosphonate treatment in women
A Bernhard, P Milovanovic, EA Zimmermann, M Hahn, D Djonic, M Krause, S Breer, K Püschel, M Djuric, M Amling, B Busse
Osteoporosis International 2013
Anti-resorptive Agents Reduce the Size of Resorption Cavities: A Three-Dimensional Dynamic Bone Histomorphometry Study
JB Matheny, CR Slyfield, EV Tkachenko, I Lin, KM Ehlert, RE Tomlinson, DL Wilson, CJ Hernandez
Bone 2013
Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: A comparison with alfacalcidol and alendronate
M Sugimoto, N Futaki, M Harada, S Kaku
Bone 2013
Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats
S Zhu, K Chen, Y Lan, N Zhang, R Jiang, J Hu
Bone 2013
The effect of resorption cavities on bone stiffness is site dependent
J Vanderoost, GH van Lenthe
Computer Methods in Biomechanics and Biomedical Engineering 2013
Proposed pathogenesis for atypical femoral fractures: Lessons from material research
B Ettinger, DB Burr, RO Ritchie
Bone 2013
Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort
BM Misof, P Roschger, D Gabriel, EP Paschalis, EF Eriksen, RR Recker, JA Gasser, K Klaushofer
Journal of Bone and Mineral Research 2013
Retrospective analysis of 27 cases of bisphosphonate-related osteonecrosis of the jaw treated surgically or nonsurgically
SY Lu, CC Liang, LH Lin
Journal of Dental Sciences 2013
Osteoporosis: Diagnosis and Management
S Silverman, S Venuturupalli
Osteoporosis: Diagnosis and Management 2013
The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits
PR Jensen, TL Andersen, BL Pennypacker, LT Duong, JM Delaissé
Calcified Tissue International 2013
Effect of alendronate on bone remodeling around implant in the rat
R Park, JH Kim, H Choi, YB Park, HS Jung, HS Moon
The journal of advanced prosthodontics 2013
Therapy for patients with CKD and low bone mineral density
SM Ott
Nature Reviews Nephrology 2013
Eliminating the need for fasting with oral administration of bisphosphonates
M Pazianas, B Abrahamsen, S Ferrari, RG Russell
Therapeutics and Clinical Risk Management 2013
Epidemiology, radiology and histology of atypical femoral fractures: Development of understanding
J Schilcher
Acta Orthopaedica 2013
Bisphosphonates and adipogenesis: Evidence for alendronate inhibition of adipocyte differentiation in 3T3-L1 preadipocytes through a vitamin D receptor mediated effect
C Mammi, M Calanchini, A Antelmi, A Feraco, L Gnessi, S Falcone, F Quintarelli, GM Rosano, A Fabbri, M Caprio
Natural Science 2013
Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice
SD Kim, HN Kim, JH Lee, WJ Jin, SJ Hwang, HH Kim, H Ha, ZH Lee
Biochemical Pharmacology 2013
Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects
K Vandyke, S Fitter, J Drew, S Fukumoto, CG Schultz, NA Sims, DT Yeung, TP Hughes, AC Zannettino
The Journal of clinical endocrinology and metabolism 2013
Spontaneous Non-Traumatic Stress Fractures in Bilateral Femoral Shafts in a Patient Treated with Bisphosphonates
DY Shin, CR Ku, KM Kim, HS Choi, Y Rhee, EJ Lee, SK Lim
The Korean Journal of Internal Medicine 2012
Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization
Y Bala, B Depalle, D Farlay, T Douillard, S Meille, H Follet, R Chapurlat, J Chevalier, G Boivin
Journal of Bone and Mineral Research 2012
Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment
JE Compston
BoneKEy Reports 2012
Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment
J Jeyabalan, M Shah, B Viollet, JP Roux, P Chavassieux, M Korbonits, C Chenu
The Journal of endocrinology 2012
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
F Jakob, H Oertel, B Langdahl, O Ljunggren, A Barrett, D Karras, JB Walsh, A Fahrleitner-Pammer, G Rajzbaum, C Barker, WF Lems, F Marin
European Journal of Endocrinology 2012
Effects of Low Dose Doxycycline and Bisphosphonate Clodronate on Gingival Levels of Matrix Metalloproteinase -9, Interleukin -1B and Alveolar Bone Loss in Diabetic Rats. A Histomorphometric and Immunohistochemical Study
SP Özdemir, B Kurtiş, G Tüter, Ş Bozkurt, SE Gültekin, B Sengüven, K Watanabe, S Aydın
Journal of Periodontology 2012
Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway
BJ Kim, YS Lee, SY Lee, SY Park, H Dieplinger, SH Ryu, K Yea, S Choi, SH Lee, JM Koh, GS Kim
Bone 2012
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women
LA Fitzpatrick, CE Dabrowski, G Cicconetti, DN Gordon, T Fuerst, K Engelke, HK Genant
Journal of Bone and Mineral Research 2012
Importance of reversible remodeling suppression with denosumab
RR Recker
IBMS BoneKEy 2012
Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces
B Hofstetter, S Gamsjaeger, RJ Phipps, RR Recker, FH Ebetino, K Klaushofer, EP Paschalis
Journal of Bone and Mineral Research 2012
Computed tomography, histological and ultrasonic measurements of adolescent scoliotic rib hump geometrical and material properties
JP Berteau, M Pithioux, H Follet, C Guivier-Curien, P Lasaygues, P Chabrand
Journal of Biomechanics 2012
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
MR McClung, A Balske, DE Burgio, D Wenderoth, RR Recker
Osteoporosis International 2012
Bone mineralization: from tissue to crystal in normal and pathological contexts
Y Bala, D Farlay, G Boivin
Osteoporosis International 2012
Understanding the influence of alendronate on the morphology and phase transformation of apatitic precursor nanocrystals
G Zhang, R Huang, Z Li, X Yang, X Chen, W Xia, X Sun, G Yang, C Gao, Z Gou
Journal of Inorganic Biochemistry 2012
Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization
Y Bala, J Kohles, RR Recker, G Boivin
Calcified Tissue International 2012
Histopathological features of bisphosphonate-associated osteonecrosis: findings in patients treated with partial mandibulectomies
YA Cho, HJ Yoon, JI Lee, SP Hong, SD Hong
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology 2012
Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude
MZ Teixeira
Homeopathy 2012
Bisphosphonates Use in Children
JF Sebestyen, T Srivastava, US Alon
Clinical Pediatrics 2012
Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis
K Henriksen, J Bollerslev, V Everts, MA Karsdal
Endocrine reviews 2011
A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice
LI Plotkin, N Bivi, T Bellido
Bone 2011
Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability
T Bellido, LI Plotkin
Bone 2011
Denosumab and bisphosphonates: Different mechanisms of action and effects
R Baron, S Ferrari, RG Russell
Bone 2011
Effect of Bisphosphonates on the Progression of Degenerative Aortic Stenosis
AL Innasimuthu, WE Katz
Echocardiography 2011
Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know
MR Allen, DB Burr
Bone 2011
A Fracture Does Not Adversely Affect Bone Mineral Density Responses after Teriparatide Treatment
A Unnanuntana, QV Ton, JP Kleimeyer, JT Nguyen, JM Lane
Clinical Orthopaedics and Related Research® 2011
Atypical diaphyseal femoral fractures—new aspects
F Feldman
Skeletal Radiology 2011
Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence – a multi-centre study
S Otto, MH Abu-Id, S Fedele, PH Warnke, ST Becker, A Kolk, T Mücke, G Mast, R Köhnke, E Volkmer, F Haasters, O Lieger, T Iizuka, S Porter, G Campisi, G Colella, O Ploder, A Neff, J Wiltfang, M Ehrenfeld, T Kreusch, KD Wolff, SR Stürzenbaum, M Schieker, C Pautke
Journal of Cranio-Maxillofacial Surgery 2011
Safety of bisphosphonates
M Pazianas, B Abrahamsen
Bone 2011
Physiology of the aging bone and mechanisms of action of bisphosphonates
LJ Dominguez, G Bella, M Belvedere, M Barbagallo
Biogerontology 2011
Bisphosphonates for postmenopausal osteoporosis
R Eastell, JS Walsh, NB Watts, E Siris
Bone 2011
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient
S Battaglia, S Dumoucel, J Chesneau, MF Heymann, G Picarda, F Gouin, N Corradini, D Heymann, F Redini
Journal of Bone and Mineral Research 2011
Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner – A quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2
FP Koch, C Merkel, B Al-Nawas, R Smeets, T Ziebart, C Walter, W Wagner
Journal of Cranio-Maxillofacial Surgery 2011
The potential value of monitoring bone turnover markers among women on alendronate
KJ Bell, A Hayen, L Irwig, MC Hochberg, KE Ensrud, SR Cummings, DC Bauer
Journal of Bone and Mineral Research 2011
Bisphosphonates and Atypical Fractures of Femur
T Yli-Kyyny
Journal of osteoporosis 2011
Effects of Short-Term Zoledronic Acid Treatment on Bone Remodeling and Healing at Surgical Sites in the Maxilla and Mandible of Aged Dogs
SS Huja, A Mason, CE Fenell, X Mo, S Hueni, AM D'Atri, SA Fernandez
Journal of Oral and Maxillofacial Surgery 2011
Medical Treatment of Osteoporotic Vertebral Fractures
BL Langdahl, T Harsløf
Therapeutic Advances in Musculoskeletal Diseases 2011
Trabecular Reorganization in Consecutive Iliac Crest Biopsies when Switching from Bisphosphonate to Strontium Ranelate Treatment
B Jobke, AJ Burghardt, B Muche, M Hahn, J Semler, M Amling, S Majumdar, B Busse, WC Chin
PloS one 2011
Obesity and osteoporosis
VN Shishkova, VN Shishkova
Osteoporosis and osteopathy 2011
Skeletal Aging and Osteoporosis
MJ Silva
2011
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis: Results of a 2-year study
R Rizzoli, RD Chapurlat, JM Laroche, MA Krieg, T Thomas, I Frieling, S Boutroy, A Laib, O Bock, D Felsenberg
Osteoporosis International 2011
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli
Burger's Medicinal Chemistry and Drug Discovery 2010
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
JJ Stepan, DB Burr, J Li, YL Ma, H Petto, A Sipos, H Dobnig, A Fahrleitner-Pammer, D Michalská, I Pavo
Osteoporosis International 2010
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
R Rizzoli, M Laroche, MA Krieg, I Frieling, T Thomas, P Delmas, D Felsenberg
Rheumatology International 2010
Effects of alendronate on bone healing after tooth extraction in rats
JI Aguirre, MK Altman, SM Vanegas, SE Franz, AC Bassit, TJ Wronski
Oral Diseases 2010
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading
A Feher, A Koivunemi, M Koivunemi, RK Fuchs, DB Burr, RJ Phipps, S Reinwald, MR Allen
Bone 2010
The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro
FP Koch, SS Yekta, C Merkel, T Ziebart, R Smeets
Head & face medicine 2010
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
M Pazianas, C Cooper, FH Ebetino, RG Russell
Therapeutics and Clinical Risk Management 2010
Radiology of Osteoporosis
G Anil, G Guglielmi, WC Peh
Radiologic Clinics of North America 2010
Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture
S Ferrari
Osteoporosis International 2010
Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate
KH Yang, SY Park, SW Park, SH Lee, SB Han, WK Jung, SJ Kim
Journal of Bone and Mineral Metabolism 2010
Use of bisphosphonates in the management of postmenopausal osteoporosis
SE Papapoulos
Annals of the New York Academy of Sciences 2010
Atypical fractures of the femur and bisphosphonate therapy
A Giusti, NA Hamdy, SE Papapoulos
Bone 2010
Bilateral Femoral Subtrochanteric Insufficiency Fractures after Long-term Bisphosphonate Therapy
JG Park, KS Song, HJ Jung, JS Lee, TJ Lee, KS Kim
Journal of the Korean Orthopaedic Association 2010
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
IR Reid, PD Miller, JP Brown, DL Kendler, A Fahrleitner-Pammer, I Valter, K Maasalu, MA Bolognese, G Woodson, H Bone, B Ding, RB Wagman, JS Martin, MS Ominsky, DW Dempster
Journal of Bone and Mineral Research 2010
Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study
RR Recker, LG Ste-Marie, B Langdahl, E Czerwinski, B Bonvoisin, D Masanauskaite, L Rowell, D Felsenberg
Bone 2010
Association between collagen cross-links and trabecular microarchitecture properties of human vertebral bone
S Viguet-Carrin, H Follet, E Gineyts, JP Roux, F Munoz, R Chapurlat, PD Delmas, ML Bouxsein
Bone 2010
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
E Shane, D Burr, PR Ebeling, B Abrahamsen, RA Adler, TD Brown, AM Cheung, F Cosman, JR Curtis, R Dell, D Dempster, TA Einhorn, HK Genant, P Geusens, K Klaushofer, K Koval, JM Lane, F McKiernan, R McKinney, A Ng, J Nieves, R O'Keefe, S Papapoulos, HT Sen, MC van der Meulen, RS Weinstein, M Whyte
Journal of Bone and Mineral Research 2010
Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women
S Qiu, RJ Phipps, FH Ebetino, S Palnitkar, DS Rao
Calcified Tissue International 2010
Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review
SJ Gallacher, T Dixon
Calcified Tissue International 2010
Bone histomorphometry: a concise review for endocrinologists and clinicians
CA Kulak, DW Dempster
Arquivos brasileiros de endocrinologia e metabologia 2010
Atlas of Postmenopausal Osteoporosis
R Rizzoli
2010
Giant osteoclast formation and long-term oral bisphosphonate therapy
RS Weinstein, PK Roberson, SC Manolagas
The New England journal of medicine 2009
Bisphosphonates and BMU birth rate: response to comments by Ott
E Seeman
Osteoporosis International 2009
Safety and Efficacy of Intravenous Zoledronic Acid in Paediatric Osteoporosis
JJ Brown, MR Zacharin
Journal of Pediatric Endocrinology and Metabolism 2009
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
KG Saag, P Geusens
Arthritis Research & Therapy 2009
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone
MR Allen, AM Erickson, X Wang, DB Burr, RB Martin, SJ Hazelwood
Calcified Tissue International 2009
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage
X Wang, AM Erickson, MR Allen, DB Burr, RB Martin, SJ Hazelwood
Journal of Biomechanics 2009
Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?
L Kolios, AK Hoerster, S Sehmisch, MC Malcherek, T Rack, M Tezval, D Seidlova-Wuttke, W Wuttke, KM Stuermer, EK Stuermer
Calcified Tissue International 2009
Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys
T Manabe, S Mori, T Mashiba, Y Cao, Y Kaji, K Iwata, S Komatsubara, T Yamamoto, A Seki, H Norimatsu
Journal of Bone and Mineral Metabolism 2009
Potential effects of bisphosphonates on bone ultrastructure
C Roux
Osteoporosis International 2009
Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy
G Favia, GP Pilolli, E Maiorano
Bone 2009
Are bisphosphonates effective and safe in patients with low serum vitamin D levels?
WF Lems, P Geusens
International Journal of Clinical Rheumatology 2009
Inhibition of osteoblast function in vitro by aminobisphosphonates
IR Orriss, ML Key, KW Colston, TR Arnett
Journal of Cellular Biochemistry 2009
Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX)
P Roschger, A Lombardi, BM Misof, G Maier, N Fratzl-Zelman, P Fratzl, K Klaushofer
Journal of Bone and Mineral Research 2009
The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits
JG Hofstaetter, J Wang, J Yan, MJ Glimcher
Osteoarthritis and Cartilage 2009
Zoledronic acid decreases bone formation without causing osteocyte death in mice
SS Huja, SA Fernandez, C Phillips, Y Li
Archives of Oral Biology 2009
Osteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review
SL Silverman, R Landesberg
The American Journal of Medicine 2009
The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
A Grey, MJ Bolland, D Wattie, A Horne, G Gamble, IR Reid
The Journal of clinical endocrinology and metabolism 2009
Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra
T Diab, MR Allen, DB Burr
Osteoporosis International 2008
In Vivo Magnetic Resonance Detects Rapid Remodeling Changes in the Topology of the Trabecular Bone Network After Menopause and the Protective Effect of Estradiol
FW Wehrli, GA Ladinsky, C Jones, M Benito, J Magland, B Vasilic, AM Popescu, B Zemel, AJ Cucchiara, AC Wright, HK Song, PK Saha, H Peachey, PJ Snyder
Journal of Bone and Mineral Research 2008
Bisphosphonat-assoziierte Osteonekrosen des Kieferknochens
MT Krauth, A Fügl, R Gruber
Wiener klinische Wochenschrift 2008
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
RG Russell, NB Watts, FH Ebetino, MJ Rogers
Osteoporosis International 2008
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
JJ Brown, L Ramalingam, MR Zacharin
Clinical Endocrinology 2008
Combination Therapy Using Exercise and Pharmaceutical Agents to Optimize Bone Health
RK Fuchs, SJ Warden
Clinical Reviews in Bone and Mineral Metabolism 2008
Bisphosphonates: how do they work?
SE Papapoulos
Best Practice & Research Clinical Endocrinology & Metabolism 2008
Surface-specific Bone Formation Effects of Osteoporosis Pharmacological Treatments
MR Allen
Clinical Reviews in Bone and Mineral Metabolism 2008
Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench
MR Allen
Cells, tissues, organs 2008
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
AL Boskey, L Spevak, RS Weinstein
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2008
Osteoporosis: how long should we treat?
A Sebba
Current Opinion in Endocrinology, Diabetes and Obesity 2008
Beneficial Effects of Combined Administration of Alendronate and Alfacalcidol on Cancellous Bone Mass of the Tibia in Orchidectomized Rats: A Bone Histomorphometry Study
J IWAMOTO, T TAKEDA, H MATSUMOTO, Y SATO, JK YEH
Journal of Nutritional Science and Vitaminology 2008
Effect of Temporal Changes in Bone Turnover on the Bone Mineralization Density Distribution: A Computer Simulation Study
D Ruffoni, P Fratzl, P Roschger, R Phipps, K Klaushofer, R Weinkamer
Journal of Bone and Mineral Research 2008
Uptake of calcium phosphate nanoshells by osteoblasts and their effect on growth and differentiation
SM Schmidt, KA Moran, AM Kent, JL Slosar, MJ Webber, MJ McCready, C Deering, JM Veranth, A Ostafin
Journal of Biomedical Materials Research Part A 2008
Zoledronic acid – does it have anabolic as well as anti-resorptive effects?
JE Compston
IBMS BoneKEy 2008
Principles of Bone Biology
CJ Rosen, T Niu
Principles of Bone Biology 2008
Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity — Observations in two elderly patients
JR Tucci
Journal of Endocrinological Investigation 2008
Teriparatide in the treatment of osteoporosis
J Stroup, MP Kane, AM Abu-Baker
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2008
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
M Visekruna, D Wilson, FE McKiernan
The Journal of clinical endocrinology and metabolism 2008
Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate
ME Arlot, Y Jiang, HK Genant, J Zhao, B Burt-Pichat, JP Roux, PD Delmas, PJ Meunier
Journal of Bone and Mineral Research 2007
1α,25-Dihydroxy-2β(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora
Y Cao, S Mori, T Mashiba, Y Kaji, T Manabe, K Iwata, K Miyamoto, S Komatsubara, T Yamamoto
Bone 2007
Recent Developments in Bisphosphonate Therapy
SL Silverman, M Maricic
Seminars in Arthritis and Rheumatism 2007
Combination therapy for treatment of osteoporosis: A review
JA Pinkerton, AC Dalkin
American Journal of Obstetrics and Gynecology 2007
Anabolic effects of bisphosphonates on peri-implant bone stock
F Knoch, C Eckhardt, CI Alabre, E Schneider, HE Rubash, AS Shanbhag
Biomaterials 2007
Alendronate Has an Anabolic Effect on Bone Through the Differentiation of Mesenchymal Stem Cells
G Duque, D Rivas
Journal of Bone and Mineral Research 2007
Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate
CJ Wang, FS Wang, KD Yang, CC Huang, MS Lee, YS Chan, JW Wang, JY Ko
Archives of Orthopaedic and Trauma Surgery 2007
Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy
L Palomo, J Liu, NF Bissada
Expert Opinion on Pharmacotherapy 2007
Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis
JJ Stepan, DB Burr, I Pavo, A Sipos, D Michalska, J Li, A Fahrleitner-Pammer, H Petto, M Westmore, D Michalsky, M Sato, H Dobnig
Bone 2007
Composite Nanocrystals Provide New Insight on Alendronate Interaction with Hydroxyapatite Structure
E Boanini, M Gazzano, K Rubini, A Bigi
Advanced Materials 2007
Effect of combined humanPTH(1–34) and calcitonin treatment in ovariectomized rats
Y Washimi, M Ito, Y Morishima, K Taguma, Y Ojima, T Uzawa, M Hori
Bone 2007
Bisphosphonate antifracture efficacy
S Adami
Bone 2007
Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure
RR Recker, PD Delmas, J Halse, IR Reid, S Boonen, PA García-Hernandez, J Supronik, EM Lewiecki, L Ochoa, P Miller, H Hu, P Mesenbrink, F Hartl, J Gasser, EF Eriksen
Journal of Bone and Mineral Research 2007
Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure
JE Compston
Bone 2007
Two-Year Changes in Bone Mineral Density and T Scores in Patients Treated at a Pharmacist-Run Teriparatide Clinic
JS Stroup, SM Rivers, AM Abu-Baker, MP Kane
Pharmacotherapy 2007
Bisphosphonate treatment and fracture repair
MM McDonald, A Schindeler, DG Little
BoneKEy-Osteovision 2007
REZUL'TATY ROSSIYSKOGO MNOGOTsENTROVOGO ISSLEDOVANIYa EFFEKTIVNOSTI I PERENOSIMOSTIBIVALOSA (STRONTsIYa RANELATA) U ZhENShchINS POSTMENOPAUZAL'NYM OSTEOPOROZOM
LY ROZhINSKAYa, SD Arapova, LK Dzeranova, NN Molitvoslovova, EI Marova, AA ShIShKINA, NI Sazonova, TO ChERNOVA, AV Il'in, LI BENEVOLENSKAYa, OA NIKITINSKAYa, TA Korotkova, NV TOROPTsOVA, AV Smirnov, NV Demin, SS Rodionova, YV BUKLEMEShEV, AA ShUMSKIY
Osteoporosis and osteopathy 2007
Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children
KM Waterhouse, A Auron, T Srivastava, C Haney, US Alon
Pediatric Nephrology 2007
Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF-II Immunoreactivity in Postmenopausal Women With Osteoporosis
YL Ma, Q Zeng, DW Donley, LG Ste-Marie, JC Gallagher, GP Dalsky, R Marcus, EF Eriksen
Journal of Bone and Mineral Research 2006
Preservation of thoracic spine microarchitecture by alendronate: Comparison of histology and microCT
LD Hordon, M Itoda, PA Shore, RC Shore, M Heald, M Brown, JA Kanis, GA Rodan, JE Aaron
Bone 2006
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis
J Iwamoto, T Takeda, Y Sato
Current Medical Research and Opinion 2006
Antiremodeling Agents Influence Osteoblast Activity Differently in Modeling and Remodeling Sites of Canine Rib
MR Allen, H Follet, M Khurana, M Sato, DB Burr
Calcified Tissue International 2006
Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs
LI Plotkin, SC Manolagas, T Bellido
Bone 2006
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients
H Dobnig, LC Hofbauer, V Viereck, B Obermayer-Pietsch, A Fahrleitner-Pammer
Osteoporosis International 2006
HRT: Have we changed?
O Conlon, K McKinney
Irish Journal of Medical Science 2006
Anabolic therapy for osteoporosis: Parathyroid hormone
F Cosman
Current Rheumatology Reports 2006
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia
K Iwata, J Li, H Follet, RJ Phipps, DB Burr
Bone 2006
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
MR Allen, K Iwata, R Phipps, DB Burr
Bone 2006
Drug Insight: bisphosphonates for postmenopausal osteoporosis
RD Chapurlat, PD Delmas
Nature Clinical Practice Endocrinology & Metabolism 2006
Drug Insight: existing and emerging therapies for osteoporosis
JE Mulder, NS Kolatkar, MS LeBoff
Nature Clinical Practice Endocrinology & Metabolism 2006
Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children
KM Waterhouse, A Auron, T Srivastava, C Haney, US Alon
Pediatric Nephrology 2006
Update of current therapeutic options for the treatment of postmenopausal osteoporosis
S Epstein
Clinical Therapeutics 2006
Predictions on Preserving Bone Mass in Knee Arthroplasty With Bisphosphonates
JS Nyman, JJ Rodrigo, SJ Hazelwood, OC Yeh, RB Martin
The Journal of Arthroplasty 2006
Osteoporosis: How Should It Be Treated?
CV Odvina
Journal of Investigative Medicine 2006
Use of Bisphosphonates to Improve the Durability of Total Joint Replacements:
AS Shanbhag
The Journal of the American Academy of Orthopaedic Surgeons 2006
Metabolic Bone Disease in Patients Receiving Home Parenteral Nutrition: A Canadian Study and Review
M Raman, E Aghdassi, M Baun, M Yeung, L Fairholm, O Saqui, JP Allard
JPEN. Journal of parenteral and enteral nutrition 2006
Selective estrogen receptor modulators (SERMS)
A Diez-Perez
Arquivos brasileiros de endocrinologia e metabologia 2006
Selective Estrogen Receptor Modulators
AC Sanchez, JC i Alsina, JL Dueñas-Díez
2006
Bisphosphonates: From Bench to Bedside
RG Russell
Annals of the New York Academy of Sciences 2006
Long-Term Safety of Bisphosphonate Therapy for Osteoporosis: A Review of the Evidence
UA Liberman
Drugs & Aging 2006
Parathyroid hormone for the treatment of osteoporosis: a systematic review.
Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D, Murray T, Hodsman A
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006
Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene
LM Helvering, R Liu, NH Kulkarni, T Wei, P Chen, S Huang, F Lawrence, DL Halladay, RR Miles, EM Ambrose, M Sato, YL Ma, CA Frolik, ER Dow, HU Bryant, JE Onyia
Molecular pharmacology 2005
Histomorphometric analysis of glucocorticoid-induced osteoporosis
LD Carbonare, F Bertoldo, MT Valenti, S Zenari, M Zanatta, S Sella, S Giannini, VL Cascio
Micron 2005
Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats
W Yao, T Hadi, Y Jiang, J Lotz, TJ Wronski, NE Lane
Osteoporosis International 2005
High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse
CY Li, RJ Majeska, DM Laudier, R Mann, MB Schaffler
Bone 2005
Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene
J Li, M Sato, C Jerome, CH Turner, Z Fan, DB Burr
Journal of Bone and Mineral Metabolism 2005
The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats
H Kajiwara, T Yamaza, M Yoshinari, T Goto, S Iyama, I Atsuta, MA Kido, T Tanaka
Biomaterials 2005
Bisphosphonate Modulates Cementoblast Behavior In Vitro
YH Chun, BL Foster, PA Lukasavage, JE Berry, M Zhao, HC Tenenbaum, MJ Somerman
Journal of Periodontology 2005
Clinical Pharmacology of Potent New Bisphosphonates for Postmenopausal Osteoporosis
RD Chapurlat
Treatments in Endocrinology 2005
Bone Remodeling at the Iliac Crest Can Predict the Changes in Remodeling Dynamics, Microdamage Accumulation, and Mechanical Properties in the Lumbar Vertebrae of Dogs
T Mashiba, S Hui, CH Turner, S Mori, CC Johnston, DB Burr
Calcified Tissue International 2005
Anabolic therapy for osteoporosis: Parathyroid hormone
F Cosman
Current Osteoporosis Reports 2005
Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study
CH Chesnut, S Majumdar, DC Newitt, A Shields, JV Pelt, E Laschansky, M Azria, A Kriegman, M Olson, EF Eriksen, L Mindeholm
Journal of Bone and Mineral Research 2005
Regulation of apoptosis in osteoclasts and osteoblastic cells
L Xing, BF Boyce
Biochemical and Biophysical Research Communications 2005
Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells
F Knoch, C Jaquiery, M Kowalsky, S Schaeren, C Alabre, I Martin, HE Rubash, AS Shanbhag
Biomaterials 2005
Emerging concepts in osteoporosis and bone strength
CD Rubin
Current Medical Research and Opinion 2005
Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters
M Arlot, PJ Meunier, G Boivin, L Haddock, J Tamayo, R Correa-Rotter, S Jasqui, DW Donley, GP Dalsky, JS Martin, EF Eriksen
Journal of Bone and Mineral Research 2005
Bone Disease of Organ Transplantation
MR Rubin, JP Billezkian
Bone Disease of Organ Transplantation 2005
A rational approach to evidence gaps in the management of osteoporosis
CJ Rosen, SA Brown
The American Journal of Medicine 2005
Bone microarchitecture evaluated by histomorphometry
LD Carbonare, MT Valenti, F Bertoldo, M Zanatta, S Zenari, G Realdi, VL Cascio, S Giannini
Micron (Oxford, England : 1993) 2005
The influence of alendronate on bone formation after autogenous free bone grafting in rats
H Altundal, B Gursoy
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology 2005
Pharmacokinetics/Pharmacodynamics of Bisphosphonates: Use for Optimisation of Intermittent Therapy for Osteoporosis
SC Cremers, GC Pillai, SE Papapoulos
Clinical Pharmacokinetics 2005
Pharmacological Management of Severe Postmenopausal Osteoporosis:
A Gaudio, N Morabito
Drugs & Aging 2005
Bone Resorption
F Bronner, MC Farach-Carson, J Rubin
2005
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
AB Hodsman, DC Bauer, DW Dempster, L Dian, DA Hanley, ST Harris, DL Kendler, MR McClung, PD Miller, WP Olszynski, E Orwoll, CK Yuen
Endocrine reviews 2005
Long-Term Safety of Bisphosphonates
SM Ott
The Journal of clinical endocrinology and metabolism 2005
The role of subchondral bone remodeling in osteoarthritis: Reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model
T Hayami, M Pickarski, GA Wesolowski, J Mclane, A Bone, J Destefano, GA Rodan, LT Duong
Arthritis & Rheumatism 2004
Cochrane Database of Systematic Reviews
L Hooper, C Bartlett, GD Smith, S Ebrahim, L Hooper
Cochrane Database of Systematic Reviews 2004
Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling
BL Riggs, AM Parfitt
Journal of Bone and Mineral Research 2004
A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage
JS Nyman, OC Yeh, SJ Hazelwood, RB Martin
Bone 2004
Bone safety of long-term bisphosphonate treatment
G Rodan, A Reszka, E Golub, R Rizzoli
Current Medical Research and Opinion 2004
Osteoblast proliferation and maturation by bisphosphonates
GI Im, SA Qureshi, J Kenney, HE Rubash, AS Shanbhag
Biomaterials 2004
Long-term effects of neridronate on human osteoblastic cell cultures
B Frediani, A Spreafico, C Capperucci, F Chellini, D Gambera, P Ferrata, F Baldi, P Falsetti, A Santucci, L Bocchi, R Marcolongo
Bone 2004
The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro
B Pan, LB To, AN Farrugia, DM Findlay, J Green, S Gronthos, A Evdokiou, K Lynch, GJ Atkins, AC Zannettino
Bone 2004
Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties
JS Day, M Ding, P Bednarz, JC van der Linden, T Mashiba, T Hirano, CC Johnston, DB Burr, I Hvid, DR Sumner, H Weinans
Journal of Orthopaedic Research 2004
The degree of mineralization is a determinant of bone strength: a study on human calcanei
H Follet, G Boivin, C Rumelhart, PJ Meunier
Bone 2004
Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition
M Chaplet, C Detry, C Deroanne, LW Fisher, V Castronovo, A Bellahcéne
Biochemical Journal 2004
Strontium ranelate: A novel mode of action leading to renewed bone quality
P Ammann
Osteoporosis International 2004
Peri-implant Bone Remodeling after Total Hip Replacement Combined with Systemic Alendronate Treatment: A Finite Element Analysis
B Peter, N Ramaniraka, LR Rakotomanana, PY Zambelli, DP Pioletti
Computer Methods in Biomechanics and Biomedical Engineering 2004
Is bone mineral density predictive of fracture risk reduction?
CA Cefalu
Current Medical Research and Opinion 2004
The effect of alendronate sodium on spinal fusion: a rabbit model
RA Lehman, TR Kuklo, BA Freedman, JR Cowart, MG Mense, KD Riew
The Spine Journal 2004
Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis
J Iwamoto, T Takeda, Y Sato, M Uzawa
Clinical Rheumatology 2004
Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib
S Komatsubara, S Mori, T Mashiba, J Li, K Nonaka, Y Kaji, T Akiyama, K Miyamoto, Y Cao, J Kawanishi, H Norimatsu
Journal of Bone and Mineral Research 2004
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
B Ettinger, SJ Martin, G Crans, I Pavo
Journal of Bone and Mineral Research 2004
Teriparatide [PTH(1-34)] Strengthens the Proximal Femur of Ovariectomized Nonhuman Primates Despite Increasing Porosity
M Sato, M Westmore, YL Ma, A Schmidt, QQ Zeng, EV Glass, J Vahle, R Brommage, CP Jerome, CH Turner
Journal of Bone and Mineral Research 2004
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
PJ Meunier, C Roux, E Seeman, S Ortolani, JE Badurski, TD Spector, J Cannata, A Balogh, EM Lemmel, S Pors-Nielsen, R Rizzoli, HK Genant, JY Reginster
New England Journal of Medicine 2004
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
HG Bone, D Hosking, JP Devogelaer, JR Tucci, RD Emkey, RP Tonino, JA Rodriguez-Portales, RW Downs, J Gupta, AC Santora, UA Liberman
New England Journal of Medicine 2004
The Xmas present for women’s health: a strike to osteoporosis prevention
M Gambacciani, AR Genazzani
Maturitas 2004
Can the increase of bone mineral density following bisphosphonates treatments be explained by biomechanical considerations?
DP Pioletti, LR Rakotomanana
Clinical Biomechanics 2004
Bisphosphonate therapy in children with osteogenesis imperfecta
F Rauch
BoneKEy-Osteovision 2004
Bone microarchitecture as an important determinant of bone strength
LD Carbonare, S Giannini
Journal of Endocrinological Investigation 2004
Encyclopedia of Endocrine Diseases
J Borén, O Wiklund
Encyclopedia of Endocrine Diseases 2004
High-dose Alendronate Uncouples Osteoclast and Osteoblast Function: A Study in a Rat Spine Pseudarthrosis Model
AA Sama, SN Khan, ER Myers, RC Huang, FP Cammisa, HS Sandhu, JM Lane
Clinical Orthopaedics and Related Research® 2004
Osteoporose-Manual
R Bartl, C Bartl
2004
Fifteen Years of Clinical Experience with Hydroxyapatite Coatings in Joint Arthroplasty
JA Epinette, MT Manley
2004
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study
RR Recker, RS Weinstein, CH Chesnut, RC Schimmer, P Mahoney, C Hughes, B Bonvoisin, PJ Meunier
Osteoporosis International 2004
RETRACTED ARTICLE: Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis
J Iwamoto, T Takeda, Y Sato, M Uzawa
Clinical Rheumatology 2004
Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism
F Rauch, H Plotkin, R Travers, L Zeitlin, FH Glorieux
The Journal of clinical endocrinology and metabolism 2003
The role of bisphosphonates in diseases of childhood
T Srivastava, US Alon
European Journal of Pediatrics 2003
Making decisions about hormone replacement therapy: bisphosphonates should not be recommended for women aged 50
SM Ott
BMJ (Clinical research ed.) 2003
Use of highly potent bisphosphonates in the treatment of osteoporosis
M McClung
Current Osteoporosis Reports 2003
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis
JJ Body
Expert Opinion on Pharmacotherapy 2003
Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis
PD Miller
Expert Opinion on Pharmacotherapy 2003
Long-Term Treatment of Incadronate Disodium Accumulates Microdamage but Improves the Trabecular Bone Microarchitecture in Dog Vertebra
S Komatsubara, S Mori, T Mashiba, M Ito, J Li, Y Kaji, T Akiyama, K Miyamoto, Y Cao, J Kawanishi, H Norimatsu
Journal of Bone and Mineral Research 2003
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal
YZ Bagger, LB Tankó, P Alexandersen, P Ravn, C Christiansen
Bone 2003
La paradójica acción, a nivel óseo, de los bisfosfonatos
HR Lenza
Revista Clínica Española 2003
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis
L Sartori, S Adami, P Filipponi, G Crepaldi
Aging clinical and experimental research 2003
Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease
Nathalie Franchimont, Ernesto Canalis
Autoimmunity Reviews 2003
Les facteurs déterminants de la résistance mécanique osseuse
P Ammann
Thérapie 2003
Bone strength and its determinants
P Ammann, R Rizzoli
Osteoporosis International 2003
Handbook of Histology Methods for Bone and Cartilage
YH An, KL Martin
2003
New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1–34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats
YL Ma, HU Bryant, Q Zeng, A Schmidt, J Hoover, HW Cole, W Yao, WS Jee, M Sato
Endocrinology 2003
Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model
J Kumer, W Yao, T Breunig, T Wronski, G Modin, JH Kinney, NE Lane
Osteoporosis International 2003
Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis
N Morabito, A Gaudio, A Lasco, C Vergara, F Tallarida, G Crisafulli, A Trifiletti, M Cincotta, MA Pizzoleo, N Frisina
Osteoporosis International 2003
The Effects of Intravenous Pamidronate on the Developing Skeleton: A Histomorphometric Study in Children and Adolescents with Osteogenesis Imperfecta
Frank Rauch, Rose Travers, Horacio Plotkin, Francis H. Glorieux
Journal of Clinical Investigation 2002
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis
EF Eriksen, F Melsen, E Sod, I Barton, A Chines
Bone 2002
Synchrotron Radiation Microtomography Allows the Analysis of Three-Dimensional Microarchitecture and Degree of Mineralization of Human Iliac Crest Biopsy Specimens: Effects of Etidronate Treatment
S Nuzzo, MH Lafage-Proust, E Martin-Badosa, G Boivin, T Thomas, C Alexandre, F Peyrin
Journal of Bone and Mineral Research 2002
Pharmacological and clinical properties of alendronate sodium hydrate
T OHTA, S KOMATSU, N TOKUTAKE
Folia Pharmacologica Japonica 2002
Bisphosphonates and Periodontics: Potential Applications for Regulation of Bone Mass in the Periodontium and Other Therapeutic/ Diagnostic Uses
HC Tenenbaum, A Shelemay, B Girard, R Zohar, PC Fritz
Journal of Periodontology 2002
Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis
PD Delmas
Bone 2002
Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis
R Rizzoli
Journal of Bone and Mineral Research 2002
Long-Term Predictions of the Therapeutic Equivalence of Daily and Less Than Daily Alendronate Dosing
CJ Hernandez, GS Beaupré, R Marcus, DR Carter
Journal of Bone and Mineral Research 2002
Raloxifene, Estrogen, and Alendronate Affect the Processes of Fracture Repair Differently in Ovariectomized Rats
Y Cao, S Mori, T Mashiba, MS Westmore, L Ma, M Sato, T Akiyama, L Shi, S Komatsubara, K Miyamoto, H Norimatsu
Journal of Bone and Mineral Research 2002
Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats
S Bourrin, P Ammann, JP Bonjour, R Rizzoli
Bone 2002
Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety
IR Reid
Expert Opinion on Drug Safety 2002
Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study
S Vedi, M Ninkovic, NJ Garrahan, GJ Alexander, JE Compston
Transplant International 2002
Prevention of Bone Loss in Ovariectomized Rats by Combined Treatment With Risedronate and 1α,25-Dihydroxyvitamin D3
RG Erben, L Mosekilde, JS Thomsen, K Weber, K Stahr, A Leyshon, SY Smith, R Phipps
Journal of Bone and Mineral Research 2002
Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women
SM Ott, A Oleksik, Y Lu, K Harper, P Lips
Journal of Bone and Mineral Research 2002
Ostéopathies et enthésopathies d’origine médicamenteuse
RM Javier, JL Kuntz
Revue du Rhumatisme 2002
Osteopenias y osteoporosis
HR Lenza
Medicine - Programa de Formación Médica Continuada Acreditado 2002
Changes in Bone Remodeling Rate Influence the Degree of Mineralization of Bone
G Boivin, PJ Meunier
Connective Tissue Research 2002
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report
J Iwamoto, T Takeda
Journal of Orthopaedic Science 2002
Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis: A Comparative Review
RB Kherani, A Papaioannou, JD Adachi
Drug Safety 2002
Alendronate Increases Bone Mass and Reduces Bone Markers in Postmenopausal African-American Women
NH Bell, JP Bilezikian, HG Bone, A Kaur, A Maragoto, AC Santora
The Journal of clinical endocrinology and metabolism 2002
Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis
S Palomba, F Orio, A Colao, C di Carlo, T Sena, G Lombardi, F Zullo, P Mastrantonio
The Journal of clinical endocrinology and metabolism 2002
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
A Cranney, G Wells, A Willan, L Griffith, N Zytaruk, V Robinson, D Black, J Adachi, B Shea, P Tugwell, G Guyatt
Endocrine reviews 2002
A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis
JJ Body, GA Gaich, WH Scheele, PM Kulkarni, PD Miller, A Peretz, RK Dore, R Correa-Rotter, A Papaioannou, DC Cumming, AB Hodsman
The Journal of clinical endocrinology and metabolism 2002
Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture
CH Chesnut, CJ Rosen
Journal of Bone and Mineral Research 2001
Statins and bones
MH Moghadasian, JJ Frohlich
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2001
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
P Roschger, S Rinnerthaler, J Yates, GA Rodan, P Fratzl, K Klaushofer
Bone 2001
The role of bisphosphonates as adjuvant therapy for breast cancer
JR Gralow
Current Oncology Reports 2001
Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate
P Ballanti, G Coen, S Mazzaferro, F Taggi, M Giustini, S Calabria, M Ferrannini, E Bonucci
Histopathology 2001
Incadronate and Etidronate Accelerate Phosphate-Primed Mineralization of MC4 Cells via ERK1/2-Cbfal Signaling Pathway in a Ras-Independent Manner: Further Involvement of Mevalonate-Pathway Blocade for Incadronate
T Fujita, N Izumo, R Fukuyama, T Meguro, C Yasutomi, H Nakamuta, M Koida
The Japanese Journal of Pharmacology 2001
How many patients are needed? Variation and design considerations in bone histomorphometry
EM Hauge, L Mosekilde, F Melsen, M Frydenberg
Bone 2001
Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles
T Mashiba, CH Turner, T Hirano, MR Forwood, CC Johnston, DB Burr
Bone 2001
A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment
CJ Hernandez, GS Beaupré, R Marcus, DR Carter
Bone 2001
The influence of bone volume fraction and ash fraction on bone strength and modulus
CJ Hernandez, GS Beaupré, TS Keller, DR Carter
Bone 2001
Alendronate: An Update of its Use in Osteoporosis
M Sharpe, S Noble, CM Spencer
Drugs 2001
Primary and Secondary Preventive Nutrition
A Bendich, RJ Deckelbaum
2001
Noninvasive Assessment of Trabecular Bone Architecture and the Competence of Bone
S Majumdar, BK Bay
2001
Fragility Fractures in Dialysis and Transplant Patients. Is it Osteoporosis, and how should it be Treated?
AB Hodsman
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2001
Bone Structure in Patients with Low Bone Mineral Density With or Without Vertebral Fractures
A Oleksik, SM Ott, S Vedi, N Bravenboer, J Compston, P Lips
Journal of Bone and Mineral Research 2000
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
PD Delmas
Bone 2000
Concentration of Bisphosphonate (Incadronate) in Callus Area and Its Effects on Fracture Healing in Rats
J Li, S Mori, Y Kaji, J Kawanishi, T Akiyama, H Norimatsu
Journal of Bone and Mineral Research 2000
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
GY Boivin, PM Chavassieux, AC Santora, J Yates, PJ Meunier
Bone 2000
Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib
T Mashiba, T Hirano, CH Turner, MR Forwood, CC Johnston, DB Burr
Journal of Bone and Mineral Research 2000
Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid-Induced Osteoporosis: A Histomorphometric Analysis of Transiliac Biopsies
PM Chavassieux, ME Arlot, JP Roux, N Portero, A Daifotis, AJ Yates, NA Hamdy, MP Malice, D Freedholm, PJ Meunier
Journal of Bone and Mineral Research 2000
Southwestern Internal Medicine Conference
MA Vazquez
The American Journal of the Medical Sciences 2000
Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk?
KG Faulkner
Journal of Bone and Mineral Research 2000
Bisphosphonates in Bone Disease
H Fleisch
Bisphosphonates in Bone Disease 2000
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
CH 3rd, S Silverman, K Andriano, H Genant, A Gimona, S Harris, D Kiel, M LeBoff, M Maricic, P Miller, C Moniz, M Peacock, P Richardson, N Watts, D Baylink
The American Journal of Medicine 2000
Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
T Schnitzer, HG Bone, G Crepaldi, S Adami, M McClung, D Kiel, D Felsenberg, RR Recker, RP Tonino, C Roux, A Pinchera, AJ Foldes, SL Greenspan, MA Levine, R Emkey, AC Santora, A Kaur, DE Thompson, J Yates, JJ Orloff
Aging clinical and experimental research 2000
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis 1
SC Manolagas
Endocrine reviews 2000
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
J Pfeilschifter, IJ Diel
Journal of Clinical Oncology 2000
The Treatment of Osteoporosis: Antiresorptive Therapy
PD Miller
Clinics in Laboratory Medicine 2000
Management of Fractures in Severely Osteoporotic Bone
K Obrant
2000
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
LI Plotkin, RS Weinstein, AM Parfitt, PK Roberson, SC Manolagas, T Bellido
Journal of Clinical Investigation 1999
Bisphosphonates: from the laboratory to the clinic and back again
RG Russell, MJ Rogers
Bone 1999
Early Estrogen Replacement Therapy Reverses the Rapid Loss of Trabecular Bone Volume and Prevents Further Deterioration of Connectivity in the Rat
NE Lane, D Haupt, DB Kimmel, G Modin, JH Kinney
Journal of Bone and Mineral Research 1999
Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach
E Hauge, L Mosekilde, F Melsen
Bone 1999
Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties
MC Monier-Faugere, Z Geng, EP Paschalis, Q Qi, I Arnala, F Bauss, AL Boskey, HH Malluche
Journal of Bone and Mineral Research 1999
Changing perceptions in osteoporosis
TJ Wilkin
BMJ (Clinical research ed.) 1999
The pharmacology of bisphosphonates and new insights into their mechanisms of action
RG Russell, MJ Rogers, JC Frith, SP Luckman, FP Coxon, HL Benford, PI Croucher, C Shipman, HA Fleisch
Journal of Bone and Mineral Research 1999
The Bisphosphonate Odyssey. A Journey from Chemistry to the Clinic
R Graham, G Russell
Phosphorus Sulfur and Silicon and the Related Elements 1999
Treatment Considerations in the Management of Age-Related Osteoporosis
NM Kaplan, BF Palmer, CD Rubin
The American Journal of the Medical Sciences 1999
Morphometric Evidence That YM175, a Bisphosphonate, Reduces Trabecular Bone Resorption in Ovariectomized Dogs With Dietary Calcium Restriction
N Ouchi, H Nishikawa, H Motoie, H Shikama
The Japanese Journal of Pharmacology 1999
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
MC Hochberg, PD Ross, D Black, SR Cummings, HK Genant, MC Nevitt, E Barrett-Connor, T Musliner, D Thompson
Arthritis & Rheumatism 1999
Pharmacological Management of Osteoporosis in Postmenopausal Women: A Comparative Review
IR Reid
Drugs & Aging 1999
Bisphosphonates
JJ Body
European Journal of Cancer 1998
Bisphosphonates and osteoporosis treatment in Italy
C Gennari, JY Reginster
Aging clinical and experimental research 1998
Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis
M Sato, TA Grese, JA Dodge, HU Bryant, CH Turner
Journal of Medicinal Chemistry 1998
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis:
JP Devogelaer
Drug Safety 1998
Osteoporosis
DL Glaser, FS Kaplan
Spine 1997
Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications
PJ Meunier, G Boivin
Bone 1997

← Previous 1 2 3 … 15 16 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 policy sources
Referenced in 1 patents
93 readers on Mendeley
See more details